Clinical Trial Update: Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) [Phase 3]

View source ↗

Summary

This Phase 3 trial update assesses the safety and immunogenicity of extended two-dose regimens of the 9-valent HPV vaccine (V503-069). The study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING